Technical Analysis for ONCE - Spark Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 51.53 0.41% 0.21
ONCE closed up 0.41 percent on Wednesday, January 17, 2018, on 68 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
2 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ONCE trend table...

Date Alert Name Type % Chg
Jan 17 Narrow Range Bar Range Contraction 0.00%
Jan 17 NR7 Range Contraction 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 16 Multiple of Ten Bullish Other 0.41%
Jan 16 Wide Bands Range Expansion 0.41%
Jan 16 Gapped Down Weakness 0.41%
Jan 12 Bearish Engulfing Bearish -2.15%
Jan 12 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.15%
Jan 12 Wide Bands Range Expansion -2.15%
Jan 11 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.70%

Older signals for ONCE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company is developing SPK-RPE65, which is in Phase III clinical trial for the treatment of inherited retinal dystrophies, a group of rare blinding conditions caused by non-sex linked, or autosomal recessive, mutations in the RPE65 gene. It is also developing SPK-CHM for the treatment of choroideremia; and preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases, as well as a pipeline of product candidates targeting rare blinding conditions. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B; and development and manufacturing collaboration with Genable Technologies Limited for the manufacture and provision of development advice in the development of Genable's therapeutic product candidate, GT038, to treat rhodopsin-linked autosomal dominant retinitis pigmentosa. The company was founded in 2013 and is based in Philadelphia, Pennsylvania.
Is ONCE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 91.75
52 Week Low 41.06
Average Volume 1,121,932
200-Day Moving Average 67.1006
50-Day Moving Average 61.8294
20-Day Moving Average 51.72
10-Day Moving Average 52.276
Average True Range 3.1833
ADX 25.96
+DI 20.58
-DI 29.08
Chandelier Exit (Long, 3 ATRs ) 47.0001
Chandelier Exit (Short, 3 ATRs ) 54.3499
Upper Bollinger Band 55.3497
Lower Bollinger Band 48.0903
Percent B (%b) 0.47
BandWidth 14.035963
MACD Line -2.4854
MACD Signal Line -3.3268
MACD Histogram 0.8413
Fundamentals Value
Market Cap 1.61 Billion
Num Shares 31.3 Million
EPS -6.39
Price-to-Earnings (P/E) Ratio -8.06
Price-to-Sales 124.29
Price-to-Book 11.08
PEG Ratio -0.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 53.77
Resistance 3 (R3) 53.79 53.07 53.39
Resistance 2 (R2) 53.07 52.50 53.06 53.27
Resistance 1 (R1) 52.30 52.15 51.94 52.28 53.14
Pivot Point 51.58 51.58 51.40 51.57 51.58
Support 1 (S1) 50.81 51.01 50.45 50.79 49.92
Support 2 (S2) 50.09 50.66 50.08 49.79
Support 3 (S3) 49.32 50.09 49.67
Support 4 (S4) 49.30